What’s The Deal With Tandem Diabetes Care Inc (NASDAQ: TNDM)?

The trading price of Tandem Diabetes Care Inc (NASDAQ:TNDM) closed lower on Tuesday, April 02, closing at $33.50, -1.03% lower than its previous close.

In examining the 52-week price action we see that the stock hit a 52-week high of $43.51 and a 52-week low of $13.82. Over the past month, the stock has gained 21.46% in value.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Tandem Diabetes Care Inc, whose market valuation is $2.20 billion at the time of this writing, is expected to release its quarterly earnings report May 01, 2024 – May 06, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.75 per share this quarter, however they have predicted annual earnings per share of -$1.61 for 2024 and -$1.09 for 2025. It means analysts are expecting annual earnings per share growth of -0.60% this year and 32.30% next year.

Analysts have forecast the company to bring in revenue of $174.25 million for the current quarter, with the likely lows of $166 million and highs of $179.8 million. The average estimate suggests sales will likely up by 2.40% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $844.94 million. The company’s revenue is forecast to grow by 13.00% over what it did in 2024.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Tandem Diabetes Care Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest TNDM has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

A quick review shows that TNDM’s price is currently 8.90% off the SMA20 and 24.34% off the SMA50. The RSI metric on the 14-day chart is currently showing 60.08, and weekly volatility stands at 6.19%. When measured over the past 30 days, the indicator reaches 6.91%. Tandem Diabetes Care Inc (NASDAQ:TNDM)’s beta value is currently sitting at 1.13, while the Average True Range indicator is currently displaying 1.99.

To see how Tandem Diabetes Care Inc stock has been performing in comparison to its peers in the industry, here are the numbers: TNDM stock’s performance was -1.03% in the latest trading, and -16.10% in the past year.

An evaluation of the daily trading volume of Tandem Diabetes Care Inc (NASDAQ:TNDM) indicates that the 3-month average is 1.88 million. However, this figure has increased over the past 10 days to an average of 1.81 million.

Currently, records show that 65.55 million of the company’s shares remain outstanding. The insiders hold 0.68% of outstanding shares, whereas institutions hold 109.00%. The stats also highlight that short interest as of Mar 15, 2024, stood at 8.08 million shares, resulting in a short ratio of 3.09 at that time. From this, we can conclude that short interest is 12.31% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 5.57 million. However, since the stock’s price has seen 13.25% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.